Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - beclometasone dipropionate, quantity: 0.1 mg/actuation - inhalation, pressurised - excipient ingredients: ethanol; norflurane - prophylactic management of asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - beclometasone dipropionate, quantity: 0.05 mg/actuation - inhalation, pressurised - excipient ingredients: ethanol; norflurane - for the prophylactic management of asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - beclometasone dipropionate, quantity: 0.05 mg/actuation - inhalation, pressurised - excipient ingredients: ethanol; norflurane - for the prophylactic management of asthma in adults. indications as at 19 july 2000: for the prophylactic management of asthma.

New Zealand - English - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - beclometasone dipropionate 50ug - nasal spray solution - 50 mcg/dose - active: beclometasone dipropionate 50ug

United States - English - NLM (National Library of Medicine)

a-s medication solutions - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 80 ug - qvar® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. important limitations of use: - qvar is not indicated for the relief of acute bronchospasm. 4.1 status asthmaticus qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. 4.2 hypersensitivity qvar is contraindicated in patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in qvar [see warnings and precautions (5.6)]. risk summary there are no adequate and well-controlled studies with qvar or beclomethasone dipropionate in pregnant women. there are clinical considerations with the use of inhaled corticosteroids (ics), including beclomethasone dipropionate, in pregnant women [see clinical considerations] . also, no published studies, including studies of large birth registries, have to date related the use of ics to any increases in congenital malformations or other

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - beclomethasone dipropionate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - beclometasone dipropionate - inhalation powder - 100microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - beclometasone dipropionate - inhalation powder - 200microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - beclometasone dipropionate - inhalation powder - 400microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - beclometasone dipropionate - inhalation powder - 200microgram/1dose